Mednax, Inc. (MD) News
Filter MD News Items
MD News Results
|Loading, please wait...|
MD News Highlights
- For MD, its 30 day story count is now at 7.
- Over the past 23 days, the trend for MD's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
Latest MD News From Around the Web
Below are the latest news stories about Mednax Inc that investors may wish to consider to help them evaluate MD as an investment opportunity.
FORT LAUDERDALE, Fla., September 08, 2021--Mednax to Present at Morgan Stanley 19th Annual Global Healthcare Conference
Robinhood Markets, Mednax, California Resources, and Other Stocks See Action From Activist Investors
Activists report to the SEC on Robinhood Markets, Oscar Health, CryoPort, Dynavax Technologies, California Resources, and Mednax
When it comes to investing, there are some useful financial metrics that can warn us when a business is potentially in...
Deutsche Bank Stick to Their Sell Rating for Mednax Inc
Teleradiology Market Share To Reach USD 11,423.4 Million By 2026 Top Key Players Siemens AG, Teleradiology Solutions (TRS), Global Diagnostics Limited., Mednax, Inc.
High target disease prevalence, product launches, increasing strategic developments such as partnerships and agreements, favorable research funding scenario and drug development pressure on pharmaceuticals due to upcoming patent expiration dates are key factors contributing to high CAGR of Teleradiology during
MEDNAX's (MD) Q2 results reflect solid volumes, partly offset by escalating expenses.
MD earnings call for the period ending June 30, 2021.
Mednax (MD) delivered earnings and revenue surprises of 24.24% and 3.72%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
FORT LAUDERDALE, Fla., August 06, 2021--Mednax Reports Second Quarter Results
In the current market session, Mednax Inc. (NYSE: MD ) is trading at $29.84, after a 1.22% drop. However, over the past month, the stock spiked by 0.61%, and in the past year, by 46.90%. Shareholders might be interested in knowing whether the stock is overvalued, even if the company is not performing up to par in the current session. Assuming that all other factors are held constant, this could present itself as an opportunity for shareholders trying to capitalize on the higher share price. The stock is currently below from its 52 week high by Full story available on Benzinga.com